

Express Mail Label No.: EV 695508619 US

Date of Deposit: October 24, 2005

Attorney Docket No.: 22058-519 CIPDIV2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Wynn et al.  
SERIAL NUMBER: 10/671,034 EXAMINER: Not yet assigned  
FILING DATE: September 25, 2003 ART UNIT: Not yet assigned  
FOR: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13 AND IL-13 RECEPTOR CHAINS

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**


Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate; and
3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 22058-519 CIPDIV2. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

  
Ivor R. Elrifi, Reg. No. 39,529  
David L. Johnson, Reg. No. 41,874  
Attorney(s) for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.


Address all written correspondence to

**Customer No.: 30623**

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: October 24, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Wynn et al.  
SERIAL NUMBER: 10/671,034 EXAMINER: Not yet assigned  
FILING DATE: September 25, 2003 ART UNIT: Not yet assigned  
FOR: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13 AND IL-13 RECEPTOR CHAINS

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**


Pursuant to the duty of disclosure under §§1.56, 1.97, and 1.98, Applicants hereby make of record the documents listed on the attached modified form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing of a first Office Action based on the merits in the above-referenced case. Accordingly, no fee or certification is believed required. Copies of the references (\*) are not provided as they were previously cited or submitted to the USPTO in prior applications, Serial No. 08/301,808, filed November 29, 1999 and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications). However, charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 22058-519 CIPDIV2.

Respectfully submitted,

Date: October 24, 2005

Ivor R. Elrifi, Reg. No. 39,529  
David E. Johnson, Reg. No. 41,874  
Attorney(s) for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
Address all written correspondence to  
**Customer No.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241



Express Mail No.: E695508619 US  
Date of Deposition: October 24, 2005

Page 1 of 1  
Attorney Docket No.: 22058-519 CIPDIV2

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/671,034
	<b>Filing Date</b>	September 25, 2003
	<b>First Named Inventor</b>	Wynn
	<b>Group Art Unit</b>	1647
	<b>Examiner Name</b>	Fozia M. Hamud
	<b>Attorney Docket Number</b>	22058-519 CIPVIV2

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

**U.S. PUBLISHED APPLICATION DOCUMENTS**

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	*B1	WO 96/04388	SMITHKLINE BEECHAM PLC; SMITHKLINE BEECHAM CORP.	02/15/96	
	*B2	WO 97/31946	GENETICS INSTITUTE	09/04/97	
	*B3	WO 97/33913	ZYMOGENETICS, INC.	09/18/97	
	*B4	WO 97/47741	SMITHKLINE BEECHAM CORP.; HUMAN GENOME SCIENCES, INC.	12/18/97	
	*B5	WO 97/47742	SMITHKLINE BEECHAM CORP.; HUMAN GENOME SCIENCES, INC.	12/18/97	
	*B6	WO 98/10638	AMRAD OPERATIONS PTY. LTD.	03/19/98	
	*B7	EP 0 812 913 A2	SMITHKLINE BEECHAM CORP.; HUMAN GENOME SCIENCES, INC.	12/17/97	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C1	Aman et al. <i>J. Biol. Chem.</i> , 271(46):29265-29270 (1996)
	*C2	Cheever et al. <i>J. Immunol.</i> , 153:753-759 (1994)
	*C3	Chiaramonte et al. <i>J. Clin. Invest.</i> , 104(6):777-785 (1999)

Express Mail No.: EV 695508619 US  
Date of Deposit: October 24, 2005

Page 2 of 1  
Attorney Docket No.: 22058-519 CIPDIV2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C4	Orchansky et al. <i>J. Biol. Chem.</i> , 274(30):20818-20825 (1999)
	*C5	Zhu et al. <i>J. Clin. Invest.</i> , 103(6):779-788 (1999)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. **08/301,808**, filed **November 29, 1999**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2085856v1